 Home > Biochemistry News > Biotechnology News > BMS Oral Kinase Inhibitor Inrebic Approved by UK NICE for Myelofibrosis

BMS Oral Kinase Inhibitor Inrebic Approved by UK NICE for Myelofibrosis

 Last Update: 2022-02-26
 Source: Internet
 Author: User

Tags

weight loss predictor

als disease symptoms

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Compilenewborn

The UK National Institute for Health and Clinical Excellence (NICE) recently issued a final assessment decision (FAD) recommending the use of Bristol-Myers Squibb's oral kinase inhibitor Inrebic (fedratinib) in the NHS for the treatment of bone marrow Fibrosis, a rare blood cancer that affects the bone marrow and disrupts the production of blood cells in the body

Symptoms of myelofibrosis are often debilitating and include fatigue, itching, weight loss, night sweats, fever, bone pain, and an enlarged spleen

Inrebic is recommended under the Cancer Drugs Fund (CDF) category for primary myelofibrosis, post-polycythemia vera myelofibrosis, and essential thrombocythemia previously treated with ruxolitinib In adult patients with post-myelofibrosis, treat disease-related splenomegaly or symptoms

Claire N.

Inrebic's active pharmaceutical ingredient is fedratinib, an oral kinase inhibitor with activity against wild-type and mutant-activated Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3)

Inrebic was obtained from Bristol-Myers Squibb's US$74 billion acquisition of Celgene.

Reference source: NICE recommends Inrebic for rare blood cancer

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.